Skip to main content

Table 1 Characteristics of study subjects

From: The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers

Sample sources

BRCA1

BRCA2

BRCA1 and BRCA2a

 

n

(% of total)

n

(% of total)

n

EMBRACE

247

(64)

92

(42)

0

kConFaB

96

(25)

84

(38)

0

AJBCS

19

(5)

22

(10)

0

ABCFS

20

(5)

23

(10)

1

Total

382

 

221

 

1

Affected breast cancerb

205

(54)

125

(57)

1

Affected ovarian cancerb

24

(6)

8

(4)

0

Number of families

257

 

118

 

1

  1. Questionnaire information on potential confounders was available for 344 BRCA1 carriers (239 EMBRACE, 80 kConFaB, 10 AJBCS and 15 ABCFS) and 200 BRCA2 carriers (92 EMBRACE, 76 kConFaB, 12 AJBCS, and 20 ABCFS). aOne individual was found to carry a deleterious mutation in both BRCA1 and BRCA2 [19]. bCancer type refers to first primary cancer diagnosis. One BRCA2 carrier with breast cancer was censored as unaffected at age of prior mastectomy. ABCFS, Australian Breast Cancer Family Study; AJBCS, Australian Jewish Breast Cancer study; EMBRACE, Evaluation of Mutant BRCA Carrier Epidemiology study; kConFaB, Kathleen Cuningham Consortium for Research into Familial Breast Cancer.